These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 32114686)

  • 21. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
    Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA
    Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of mineralocorticoid receptor antagonists in kidney diseases.
    Patel V; Joharapurkar A; Jain M
    Drug Dev Res; 2021 May; 82(3):341-363. PubMed ID: 33179798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist.
    Iijima T; Katoh M; Takedomi K; Yamamoto Y; Akatsuka H; Shirata N; Nishi A; Takakuwa M; Watanabe Y; Munakata H; Koyama N; Ikeda T; Iguchi T; Kato H; Kikkawa K; Kawaguchi T
    J Med Chem; 2022 Jun; 65(12):8127-8143. PubMed ID: 35652647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonsteroidal antagonists of the mineralocorticoid receptor.
    Kolkhof P; Nowack C; Eitner F
    Curr Opin Nephrol Hypertens; 2015 Sep; 24(5):417-24. PubMed ID: 26083526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.
    Cohen S; Sternlicht H; Bakris GL
    Curr Diab Rep; 2022 May; 22(5):213-218. PubMed ID: 35441935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.
    Wan N; Rahman A; Nishiyama A
    J Hum Hypertens; 2021 Feb; 35(2):148-156. PubMed ID: 32661269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
    Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
    Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences.
    Yang J; Young MJ
    Curr Opin Pharmacol; 2016 Apr; 27():78-85. PubMed ID: 26939027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Approaches towards tissue-selective pharmacology of the mineralocorticoid receptor.
    Clarisse D; Deng L; de Bosscher K; Lother A
    Br J Pharmacol; 2022 Jul; 179(13):3235-3249. PubMed ID: 34698367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
    Kintscher U
    Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Kintscher U; Bakris GL; Kolkhof P
    Br J Pharmacol; 2022 Jul; 179(13):3220-3234. PubMed ID: 34811750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonsteroidal Mineralocorticoid Receptor Antagonist Eliciting Cardiorenal Protection Is a New Option for Patients with Chronic Kidney Disease.
    Liu W; Yu S
    Kidney Dis (Basel); 2023 Jan; 9(1):12-25. PubMed ID: 36756081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent progress in the diagnosis and treatment of primary aldosteronism.
    Yoshida Y; Shibata H
    Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
    Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
    Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?
    Manolis AA; Manolis TA; Melita H; Manolis AS
    Curr Hypertens Rep; 2019 Mar; 21(3):22. PubMed ID: 30826898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mineralocorticoid Receptor Antagonists in the Management of Heart Failure and Resistant Hypertension: A Review.
    Flatt DM; Brown MC; Mizeracki AM; King BJ; Weber KT
    JAMA Cardiol; 2016 Aug; 1(5):607-12. PubMed ID: 27434136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
    Yugar-Toledo JC; Modolo R; de Faria AP; Moreno H
    Vasc Health Risk Manag; 2017; 13():403-411. PubMed ID: 29081661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease.
    Kawanami D; Takashi Y; Muta Y; Oda N; Nagata D; Takahashi H; Tanabe M
    Front Pharmacol; 2021; 12():754239. PubMed ID: 34790127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.